On Friday 1st June 2018

“On Friday 1st June 2018, Merck/Pfizer announced that the current BAVENCIO (avelumab) metastatic Merkel cell carcinoma access program in Australia will be closed. Any patient request already approved on the access program was grandfathered on Friday, 1st June, and...